 Lille, France; Cambridge, MA; January 8, 2021 - GENFIT Nasdaq and Euronext: GNFT, a late-stage biopharmaceutical company dedicated to improving the lives of patients with metabolic and liver diseases the Company, today informs its shareholders of certain changes in certain of the participation and organization procedures for the extraordinary general meeting of January 13, 2021 the Extraordinary General Meeting, following the publication of decree n 2020-1614 of December 18, 2020 extending and modifying decree n 2020-418 of April 10, 2020 specifying the procedures for holding meetings behind closed doors the Decree. Consequently, the procedures for participation in the Extraordinary General Meeting indicated in this press release proxy representation, written questions, composition of the Committee and broadcast details supplement those set out in the notice avis published in the Bulletins des Annonces Légales Obligatoires, no. 146 dated December 7, 2020. 